Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)

Presentación del tema: "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)"— Transcripción de la presentación:

1 Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)
Dra. Elvira del Barco Morillo. Hospital Clínico Universitario. Salamanca

2 Congresos Nacionales TTCC
1º International Congress Of Head and neck Febrero 2000 2001 Grupo Cooperativo con 15 miembros Congresos Nacionales TTCC 2005_Barcelona 2007_Salamanca 2009_Zaragoza 2011_Valencia

3 ACTIVIDADES FORMACIÓN DIVULGACIÓN PREVENCIÓN DIAGNÓSTICO TRATAMIENTO
The TTCC believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

4 PREVENCIÓN, PRESERVACIÓN, LOCOREGIONAL Y METASTÁSICO
Ensayos clínicos PREVENCIÓN, PRESERVACIÓN, LOCOREGIONAL Y METASTÁSICO Cerrados: 5 Abiertos: 3 Aprobado por el CEC: 2 Más de 1000 enfermos The TTCC believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

5 LOGROS EN INVESTIGACIÓN
GRUPOS COOPERATIVOS INVESTIGACIÓN BASICA TRASLACIONAL QTI / nuevos fármacos DIANAS MOLECULARES RDT QTRDT RT-E SOPORTE CIRUGÍA

6 LOGROS EN INVESTIGACIÓN
GRUPOS COOPERATIVOS A randomized phase II, multicenter trial of induction with Cisplatin/ Docetaxel verus Cisplatin/5-fluorouracil for patients with locally advanced head and neck carcinoma. February 2000 and July 2001, 84 patients TAX-ES-202. Publicado en Eur J Cancer Jun;41(9): A randomized, multicenter phase III trial comparing induction chemotherapy with Cisplatin/5-FU (PF) or Docetaxel/Cisplatin/5-FU (TPF) plus chemotherapy (CRT) versus CRT alone as fisrt-line treatment of unresectable locally advanced head and neck cancer. XRP6976F / COMUNICACIÓN ORAL ASCO 2006. Phase II study of combination Cetuximab and weekly Paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck ERBITAX. ASCO Pendiente publicación Phase II study of Capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional and/or metastatic relapse after previous Platinium-based treatment. XEL-CYC-TTCC. POSTER ASCO Pendiente publicación A single arm, multicenter, phase II trial to evaluate the combination of cetuximab plus taxotere (T), cisplatin (P) and 5-fluorouracil (F) (TPF) as induction chemotherapy in patients (pts) with unresectable squamous cell carcinoma of the head and neck. NEO-TPFE-TTCC. Póster discusión ASCO Resultados preliminares XRP6976F / COMUNICACIÓN ORAL ASCO Pendiente publicación   The TTCC believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

7 LOGROS EN INVESTIGACIÓN
GRUPOS COOPERATIVOS Estudios abiertos An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy in Locally Advanced, Unresectable Head and Neck Cancer. TTCC (ClinicalTrials.gov Identifier: NCT ) A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy. TTCC ( ClinicalTrials.gov Identifier: NCT ) An Open Label Randomized, Phase III Trial With Erlotinib (Tarceva®) as Maintenance Treatement in Patients With Operated Squamous Cell Carcinoma of the Head and Neck and treated with Chemo-radiotherapy or Radiotherapy with Curative Purposes. ML (Nº EudraCT: )

8 LOGROS EN INVESTIGACIÓN
GRUPOS COOPERATIVOS Panitumumab EN METASTÁSICOS EN LOCALMETE AVANZADOS Lapatinib CANCER DE TIROIDES CANCER DE NASOFARINGE